The company's principal activity is to discover and develop pharmaceutical products that restore innate defense mechanisms of mucosal hydration and mucociliary clearance, as well as other non-mucosal disorders. The company is in the development stage. The company's lead products target respiratory and ophthalmic diseases. The company currently has five product candidates in clinical development.